Skip Navigation


JAC Advance Access originally published online on June 7, 2005
Journal of Antimicrobial Chemotherapy 2005 56(1):1-5; doi:10.1093/jac/dki184
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
56/1/1    most recent
dki184v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Winston, A.
Right arrow Articles by Boffito, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Winston, A.
Right arrow Articles by Boffito, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

Leading article

The management of HIV-1 protease inhibitor pharmacokinetic interactions

Alan Winston and Marta Boffito*

St Stephen's Centre, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK

* Corresponding author. Tel: +44-20-8846-6507; Fax: +44-20-8746-5603; E-mail: martalbb{at}hotmail.com

The HIV-1 protease inhibitors (PIs) are widely used in combination antiretroviral therapy for the management of HIV-1 infection. Certain characteristics of the PIs, in particular their metabolism being mainly via the cytochrome P450 isoenzyme group and their gastric absorption being pH dependent, make them prone to clinically significant drug interactions with other antiretrovirals, concomitant medication and complementary treatments. Owing to the nature of the disease, individuals with HIV are frequently prescribed complex treatment regimens (both for the management of intolerance, toxicity and viral resistance to antiretroviral therapy, and in the management of co-morbid states) that may interact with PI therapy. For many of these potential interactions, few data are available. This review will focus on the current use of PIs, highlighting some important management issues encountered with common pharmacokinetic interactions seen in clinical practice.

Keywords: drug–drug interactions , antiretroviral , HIV therapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Clin PharmacolHome page
V. J. Sekar, S. Spinosa-Guzman, E. De Paepe, M. De Pauw, T. Vangeneugden, E. Lefebvre, and R. M. W. Hoetelmans
Darunavir/Ritonavir Pharmacokinetics Following Coadministration With Clarithromycin in Healthy Volunteers
J. Clin. Pharmacol., January 1, 2008; 48(1): 60 - 65.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. Devadas and S. Dhawan
Hemin Activation Ameliorates HIV-1 Infection via Heme Oxygenase-1 Induction
J. Immunol., April 1, 2006; 176(7): 4252 - 4257.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.